T Cell Modulation in Immunotherapy Approaches

Modulation of T cell activity lies at the heart of modern immunotherapy, harnessing the body’s own defences to combat cancer, persistent viral infections and other diseases. Strategies centre on the balancing act between activating co-stimulatory pathways and blocking inhibitory signals so that effector T cells can expand, differentiate into cytotoxic phenotypes and form durable memory pools. The tumour microenvironment often subverts these responses by upregulating inhibitory checkpoints or recruiting regulatory T cells, leading to T cell exhaustion and loss of antitumour efficacy. Recent developments have focused on engineering novel agonists that cluster tumour necrosis factor receptor superfamily members, optimising combination regimens of co-stimulatory and checkpoint blockade antibodies, and exploiting dynamic biomarkers on circulating and tumour-infiltrating lymphocytes to personalise therapy. Preclinical and early-phase clinical trials demonstrate that fine-tuning T cell receptor signalling, together with precise engagement of accessory molecules such as OX40, 4-1BB and GITR, can restore robust T cell immunity, reshape the suppressive microenvironment and achieve superior clinical outcomes.

Research from Nature Portfolio

Neoadjuvant administration of an agonist antibody targeting the co-stimulatory receptor OX40 prior to surgical resection in head and neck squamous cell carcinoma patients has been shown to be safe and to enhance both CD4+ and CD8+ T cell proliferation in blood and tumour tissue. Post-treatment biopsies reveal increased infiltration by activated conventional CD4+ tumour-infiltrating lymphocytes and expansion of tumour-reactive CD103+ CD39+ CD8+ cells, suggesting that early engagement of OX40 can augment tumour antigen-specific immunity and may serve as a biomarker for clinical activity. These findings underscore the translational potential of preoperative T cell modulation and highlight the value of dynamic immunomonitoring in guiding combination strategies.

T Cell Modulation in Immunotherapy Approaches publication trend

The graph below shows the total number of articles in t cell modulation in immunotherapy approaches across all publications each year (not limited to Nature Index journals).

Technical terms

Co-stimulatory receptor: A surface molecule on T cells (e.g. OX40, 4-1BB) that provides an activating signal essential for full T cell activation and survival.

Immune checkpoint inhibitor: An antagonist antibody that blocks inhibitory pathways (e.g. PD-1, CTLA-4) to relieve suppression of T cell effector functions.

Tumour microenvironment: The complex milieu of immune cells, stromal components and soluble factors surrounding tumour cells that influences immune responses.

Regulatory T cell (Treg): A specialised subset of CD4+ T cells that suppresses immune activation and maintains peripheral tolerance.

Tumour-infiltrating lymphocyte (TIL): Lymphocytes that have migrated into tumour tissue and can mediate antitumour immunity when appropriately activated.

References

1. From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review. Journal of Experimental & Clinical Cancer Research (2024).
2. Engineering nano‐clustered multivalent agonists to cross‐link TNF receptors for cancer therapy. Aggregate (2023).
3. OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum. Cell Reports Medicine (2023).
4. OX40/OX40 ligand and its role in precision immune oncology. Cancer and Metastasis Reviews (2024).
5. Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells. Nature Communications (2021).